Suramin-induced growth inhibition and insulinlike growth factor-I binding blockade in human breast carcinoma cell lines: potentially related events

Federica Ravera, Loredana Miglietta, Paolo Pirani, Silvano Ferrini, Roberto E. Favoni

Research output: Contribution to journalArticle

Abstract

Suramin, a polyanionic drug used in the treatment of trypanosomiasis and onchocerciasis, inhibits growth factor-induced mitogenesis in several human tumours. We have investigated the effect of suramin on human breast cancer cell lines (HBCCL). By cell counts and thymidine incorporation we found that 50 to 400 μg/ml suramin inhibits the proliferation of HBCCL in a dose-dependent and reversible fashion (id50 ≈ 200 μg/ml for MCF-7 and MDA-MB 231). Radioreceptor and affinity cross-linking assays showed that suramin was also able to reduce the binding of insulin-like growth factor I (IGF-I) to its receptor (40-50% inhibition at 100 μg/ml). Our results indicate that the drug does not affect the IGF-I receptor (IGF-I-R), but binds directly to the IGF-I peptide. In conclusion, the strict correlation observed between suramin inhibition of proliferation and IGF-I binding on HBCCL suggests a possible therapeutic role for this molecule as an antineoplastic drug in human breast tumours.

Original languageEnglish
Pages (from-to)225-230
Number of pages6
JournalEuropean Journal of Cancer
Volume29
Issue number2
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Suramin-induced growth inhibition and insulinlike growth factor-I binding blockade in human breast carcinoma cell lines: potentially related events'. Together they form a unique fingerprint.

Cite this